Menopausal Hot Flashes Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Menopausal Hot Flashes Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The menopausal hot flashes market is projected to register a CAGR of 3.4% during the forecast period, 2022-2027.

Although the COVID-19 epidemic has continued to reverse the growth of various markets, the current impact of the outbreak varies. The high pressure for hospitals to provide services to COVID-19 patients was one of the main barriers to hospitals and clinics providing women's health services. According to the study titled "Inactive Lifestyles Lead to More Frequent, Severe Hot Flashes: Study" published in September 2021, in the age of COVID-19 sedentary behavior, working from home, traveling less has increased the prevalence of hot flashes and menopause in women, which has significantly impacted the market.

Increased incidence of menstrual fever, increased authorization of new therapies, and increased awareness of menopause health are important factors in driving the menopausal hot flashes market. Hot flashes are a feeling of sudden warmth, often intense on the chest, neck, and face. The heat causes redness of the skin (called flatulence) and excessive sweating. Hot flashes often occur as a result of menopause when menstruation is abnormal and eventually stops. Fever is the most common sign of menopause (including stages such as menopause, menopause, and post-menopause). The occurrence of hot flashes varies between women and can range from a few weeks to a few hours. Some of the symptoms of hot flashes are rapid heartbeat, red, swollen skin, sweating, especially in the upper extremities, the rapid sensation of warmth spreading over the face and face, and so on. Hot temperatures can vary in intensity and frequency. On average, fever symptoms persist for more than seven years or sometimes in some women, possibly for more than 10 years. Hot flashes are caused by changes in fertility hormones, which are more sensitive to small changes in body temperature. Factors such as smoking, obesity, and racism may increase the risk of hot flashes.

According to the study "Frequent hot flashes in women, 40 to 65 years of age with metabolic syndrome" published in December 2020, women over the age of 40 are more likely to have a fever, about 55.83%, and appear to be associated with metabolic syndrome.

In addition, according to a study "Hot Flashes" updated in December 2021 published in the National Center for Biotechnology Information (NCBI), hot flashes were among the most common types of menopausal vasomotor (VMS) symptoms, affecting up to 74% of perimenopausal women. About 65% of women complain of hot flashes for more than two years and 36% cry for more than five years. Therefore, the increasing incidence of menopausal vasomotor symptoms serves as a major factor contributing to the market growth of menopausal hot flashes.

Additionally, the increasing focus on research for the development of treatment of hot flashes is also propelling the growth of the market. For Instance, in December 2021, Acer Therapeutics Inc. received United States Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for its selective non-peptide neurokinin 3 receptors (NK3R) antagonist, ACER-801 (osanetant), for the potential treatment of induced Vasomotor Symptoms (iVMS).

Thus, due to the above-mentioned factors, the studied market is expected to witness significant growth during the study period. However, the side effects associated with hormone products and the availability of generic drugs are limiting factors to the growth of the market.

Key Market TrendsThe Estrogen Segment is Expected to Hold a Major Market Share in the Market

The COVID-19 epidemic has affected the supply chain of pharmaceutical products. The restrictions on the production and export of medicines have affected many imported products, such as the United States, Europe, and other countries. Some of the medicines are manufactured indoors by pharmaceutical companies, and some of the company's medicines are manufactured with foreign materials, such as contract production services, which also contributed to the supply of products.

Estrogen supplements help to increase female hormone levels and reduce the symptoms of menopause, including fever. Some of the United States Food and Drug Administration-approved estradiol-containing heat treatments are Alora, Estraderm, Estrogel, Evamist, Vivelle, Climara, Divigel, and Estrace.

According to the article "Hormone therapy: Is it right for you?" published in June 2020, systemic estrogen therapy remains the most effective treatment for the relief of troublesome menopausal hot flashes and night sweats. It can also ease vaginal symptoms of menopause, such as dryness, itching, burning, and discomfort with intercourse. Thus, the estrogen component plays a major role in the market for menopausal hot flashes and is expected to show a similar trend in the forecast period.

Additionally, the study "Treatment of menopausal symptoms with hormone therapy" published in June 2020 suggested that estrogen is the most effective treatment available for relief of hot flashes and other menopausal symptoms as well such as vulvovaginal atrophy, including vaginal dryness and dyspareunia.

Some of the benefits associated with estrogen medications include improving the health of the vagina, reducing the symptoms of menopause, and possibly promoting bone and heart health.

Novartis AG provides "Vivelle-DOT (estradiol transdermal system)" which is used to treat moderate and severe vasomotor symptoms due to menopause and to treat moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. In addition, the company Novo Nordisk Corporation offers a "Vagifem" 10 mcg tablet for vagin that treats changes in and around the vagina that occur after menopause and treats a combination of vaginal symptoms.

Therefore, the increased incidence of menopausal fever and technological advances in the development of new drugs by emerging athletes in the market are the main components of the estrogen component.

North America is Expected to Hold a Significant Share in the Market and Continue the Trend over the Forecast Period

North America is expected to hold a major market share in the menopausal hot flashes market due to the increased incidence of menopause, increased awareness of menopause, and the presence of a large percentage of older women in the region. According to the February 2022 update of "Menopause (Nursing)" by Kimberly Peacock et al., stated that in the United States, about 1.3 million women stop menstruating each year, starting between the ages of 51 and 52 years. According to the same source, about 5% of women experience premature menopause between the ages of 40 and 45.

In addition, good government-initiated policies, such as Healthy People 2020, developed by the Department of Health and Human Services, which has a 10-year plan to improve the health of all Americans, are likely to further market growth.

Furthermore, the launch of products and approvals from the regulatory authority also propel the growth of the market. For Instance, in May 2021, TherapeuticsMD, Inc. submitted a supplemental New Drug Application (“sNDA”) for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg, to the United States Food and Drug Administration (“FDA”). BIJUVA is the only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule. It is taken once daily for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.

Thus, owing to the abovementioned factors, the market is expected to grow in the North American region over the forecast period.

Competitive Landscape

The menopausal hot flashes market is fragmented and competitive and consists of several major players. A large portion of the market share is taken up by small and mid-sized companies that produce generic treatment options. Some of the companies currently dominating the market are AbbVie Inc. (Allergan PLC), Bayer AG, Novartis AG, Pfizer Inc., Novo Nordisk Corporation, Hisamitsu Pharmaceutical Co. Inc., Merck & Co. Inc., and Teva Pharmaceutical Industries Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.